Pre-Emptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial

CONCLUSION: Pre-emptive clobetasol might lessen regorafenib-induced hand-foot reactions compared with reactive therapy. Further confirmatory studies are needed in a larger patient cohort.IMPLICATIONS FOR PRACTICE: Regorafenib causes hand-foot skin reactions. Pre-emotive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event. Although further study is needed, the favorable adverse event profile of this intervention might prompt clinicians to discuss this option with their patients.PMID:33604969 | DOI:10.1002/onco.13730

Source: The Oncologist - February 19, 2021 Category: Cancer & Oncology Authors: Aminah Jatoi Fang-Shu Ou Daniel H Ahn Tyler J Zemla Jennifer G Le-Rademacher Patrick Boland Kristen K Ciombor Nisha L Jacobs Boris Pasche James M Cleary Jeannine S McCune Katrina S Pedersen Afsaneh Barzi E Gabriela Chiorean Erica N Heying Heinz-Josef Lenz Source Type: research